Uptake and Competition Among Biosimilar Biological Products in the US Medicare Fee-for-Service Population-Reference-Cited by-同舟云学术

Uptake and Competition Among Biosimilar Biological Products in the US Medicare Fee-for-Service Population

Published:2022-06-01 Issue:16 Volume:37 Page:4292-4294
ISSN:0884-8734
Container-title:Journal of General Internal Medicine
language:en
Short-container-title:J GEN INTERN MED

Author:

Kozlowski Steven^ORCID,Flowers Natasha,Kwist Andrew,Dutcher Sarah K.,Wernecke Michael,Kelman Jeffrey A.,Graham David J.

Funder

FDA and CMS Interagency Agreement

Publisher

Springer Science and Business Media LLC

Subject

Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s11606-022-07670-7.pdf

Reference6 articles.

1. 2021 Biosimilars Trends Report. 2021; https://www.amgenbiosimilars.com/commitment/-/media/Themes/Amgen/amgenbiosimilars-com/Amgenbiosimilars-com/pdf/USA-CBU-80962_Amgen-2021-Biosimilar-Trends-Report.pdf. Accessed 04/27/2022.

2. Yu Y, Gupta S. Pioneering advantage in generic drug competition. International Journal of Pharmaceutical and Healthcare Marketing. 2014;8(2):126-150.

3. Porath D. Size and dynamics of order-of-entry effects in pharmaceutical markets. International Journal of Market Research. 2018;60(1):50-66.

4. Grabowski H, Long G, Mortimer R, Boyo A. Updated trends in US brand-name and generic drug competition. J Med Econ. 2016;19(9):836-844.

5. Regnier SA, Ridley DB. Market watch: forecasting market share in the US pharmaceutical market. Nat Rev Drug Discov. 2015;14(9):594-595.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Cost of Inflammatory Bowel Disease Care – How to Make it Sustainable;Clinical Gastroenterology and Hepatology;2024-08

2. Biosimilar Uptake in Medicare Advantage vs Traditional Medicare;JAMA Health Forum;2023-12-28